Observational studyActa oncologica (Stockholm, Sweden)2026
FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland.
Observational study in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe aim of the study was to compare overall survival (OS) and time to next treatment (TTNT) of epidermal growth factor receptor (EGFR) mutation positive Non-Small Cell Lung Cancer (NSCLC) patients from start of first therapy, by EGFR mutational sub-type, disease stage at first diagnosis (early vs. advanced stage), first treatment and metastatic sites. Patient/material and methods: This retrospective observational study utilized patient-level data from hospital data lakes at two university hospital districts in Southern Finland on EGFR-mutation-positive NSCLC patients diagnosed between 2017 and 2023. OS and TTNT were analysed from start of first therapy using Kaplan-Meier, multivariable Cox proportional hazard models and log-rank test.
resultsAmong 544 EGFR-mutant NSCLC patients, 42% had early-stage disease. In early-stage NSCLC, OS did not differ significantly between Del19 and L858R mutations, and surgery was the only initial treatment associated with improved OS, with Del19 providing no additional survival benefit. In advanced-stage NSCLC, L858R mutation was a risk factor for shorter OS compared to Del19 (hazard ratio [HR]: 2.01 95% confidence interval [CI]: 1.34-3.02, p = 0.001). First-line third-generation tyrosine kinase inhibitor (TKI) showed improved OS compared to first-generation TKI (HR: 0.46 95% CI: 0.28-0.78, p = 0.004). Younger patients more often had central nervous system (CNS) and bone metastases. CNS and liver metastases at diagnosis were linked to shorter OS (5.0 and 8.1 months, respectively).
interpretationEGFR subtype did not affect outcomes in early-stage NSCLC, while Del19 mutations and first-line third-generation TKIs were associated with better outcomes in advanced disease. Younger patients had higher rates of CNS and bone metastases, which were associated with shorter OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.